Seitz, Helmut K.
Bataller, Ramon
Cortez-Pinto, Helena
Gao, Bin
Gual, Antoni
Lackner, Carolin
Mathurin, Philippe
Mueller, Sebastian
Szabo, Gyongyi
Tsukamoto, Hidekazu
Article History
First Online: 16 August 2018
Change Date: 28 August 2018
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41572-018-0021-8
Competing interests
: H.K.S. has received lecture fees from the Falk Foundation and research grants from Octapharma. R.B. has no conflicts of interest. H.C.-P. has received lecture fees and advisory board fees from Genfit, Gilead Sciences, Intercept Pharmaceuticals and Merck. She is also the Policy Councillor for the European Association for the Study of the Liver. B.G. has no conflicts of interest. A.G. has received honoraria and grants for research from D&A Pharma SAS and Lundbeck Limited. He was also principal investigator in one of the nalmefene pivotal studies, investigator in the sodium oxybate trial and Spanish coordinator of the acamprosate trial (Adisa study). He is a past president of the European Federation of Addiction Societies and vice president of the International Network on Brief Interventions for Alcohol and Drugs. C.L. has no conflicts of interest. P.M. consults for Gilead Sciences and Verlyx Pharma. S.M. has previously been an adviser for Echosens. G.S. has received US NIH grant funding from the National Institute on Alcohol Abuse and Alcoholism, is employed by the University of Massachusetts Medical School and is the Editor-in-Chief of <i>Hepatology Communications</i> of the American Association for the Study of Liver Disease. H.T. has received grants and donations from EA Pharma, Gilead Sciences and Otsuka Pharmaceutical.